Melbourne, Sep 20, 2010 (ABN Newswire) - Clinical advances by regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) were featured prominently at the 39th annual meeting of the International Society for Experimental Hematology (ISEH) and the Tissue Engineering and Regenerative Medicine International Society (TERMIS) Asia Pacific meeting, both held over the past several days.
